Channel SR 90mg Tablet (Diltiazem 90mg)

Description

Channel SR 90mg Tablet (Diltiazem 90mg) — Complete Clinical and Patient Information Guide

Product Overview

Channel SR 90mg Tablet (Diltiazem 90mg) contains Diltiazem Hydrochloride 90mg sustained-release as its active pharmaceutical ingredient, belonging to the non-dihydropyridine calcium channel blocker (benzothiazepine class) — rate-slowing CCB. It is clinically indicated for stable angina pectoris, vasospastic (Prinzmetal’s) angina, hypertension, and rate control in supraventricular arrhythmias (atrial fibrillation/flutter, paroxysmal SVT). This guide has been prepared in accordance with YMYL (Your Money Your Life) content standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established cardiovascular clinical guidelines.

Channel SR 90mg contains diltiazem 90mg — a non-dihydropyridine calcium channel blocker with balanced cardiac (rate-slowing) and vascular (vasodilatory) effects. The extended-release/CD formulation provides once-daily convenience with consistent 24-hour drug levels and the best tolerability profile.

About Channel SR 90mg and Its Active Ingredient

Diltiazem Hydrochloride 90mg sustained-release is the pharmacologically active compound in Channel SR 90mg. Cardiovascular medications are among the most safety-critical drugs prescribed — interactions with other heart medications, anticoagulants, and antihypertensives can have life-threatening consequences, and abrupt discontinuation of certain cardiac drugs (beta-blockers, anticoagulants) without medical guidance can precipitate dangerous rebound phenomena. All cardiovascular pharmacotherapy decisions require specialist or physician oversight, with regular monitoring and dose optimisation based on clinical response, ECG findings, blood pressure recordings, and relevant biochemical parameters.

Mechanism of Action

Diltiazem is a non-dihydropyridine (phenylalkylamine-class adjacent — benzothiazepine class) calcium channel blocker with a balanced cardiovascular pharmacological profile encompassing both vascular and cardiac effects. It blocks L-type voltage-gated calcium channels in cardiac myocytes and vascular smooth muscle, but its pharmacological balance between cardiac and vascular effects is intermediate between verapamil (primarily cardiac) and dihydropyridine CCBs like amlodipine (primarily vascular). In the heart, diltiazem inhibits calcium entry in sinoatrial (SA) and atrioventricular (AV) nodal cells, reducing heart rate (negative chronotropy) and slowing AV conduction (negative dromotropy) — effects that make it valuable for rate control in atrial fibrillation and flutter, SVT suppression, and control of symptoms in hypertrophic cardiomyopathy. In the coronary and peripheral vasculature, diltiazem blocks L-type calcium channels in smooth muscle, producing coronary vasodilation (relieving coronary vasospasm in Prinzmetal’s angina and providing anti-anginal effect) and mild peripheral vasodilation (lowering blood pressure). This combination of rate-slowing cardiac effects plus vasodilation makes diltiazem particularly effective in stable angina (both reducing oxygen demand through rate reduction and increasing supply through coronary dilation), vasospastic angina, and mild hypertension where rate control is also desirable.

A clear understanding of the pharmacological mechanism helps explain the clinical requirements: why timing, dose titration, monitoring, drug interactions, and contraindications exist. Healthcare providers use mechanistic knowledge to individualise therapy, anticipate interactions, and monitor for treatment response and toxicity.

Clinical Indications

Channel SR 90mg Tablet (Diltiazem 90mg) is clinically indicated for:

• Primary indication: stable angina pectoris, vasospastic (Prinzmetal’s) angina, hypertension, and rate control in supraventricular arrhythmias (atrial fibrillation/flutter, paroxysmal SVT)
• Specialist assessment required: Cardiovascular drug therapy must be initiated and monitored by a qualified cardiologist, physician, or specialist. Self-diagnosis and self-treatment of cardiac conditions is dangerous and may delay life-saving treatment.

Dosage and Administration

SR/CD formulations provide once or twice daily dosing. Swallow whole — do not crush or chew SR/CD capsules/tablets. Dose titrated based on heart rate, blood pressure, and anginal symptom control. Dilzem is the original brand-name diltiazem from RPG/Sanofi in India.

Never adjust the dose or stop cardiovascular medications without consulting your prescribing physician. Abrupt withdrawal of beta-blockers, anticoagulants, and anti-anginal drugs can cause dangerous rebound phenomena including angina exacerbation, myocardial infarction, and thromboembolic events.

Who Should Use Channel SR 90mg

Channel SR 90mg is indicated for adult patients in whom the relevant cardiovascular condition has been confirmed by clinical assessment and appropriate investigations (ECG, echocardiogram, cardiac biomarkers, blood pressure recording, coagulation studies as applicable) and in whom this specific pharmacological approach has been determined to be clinically appropriate after benefit-risk assessment.

Contraindications

Hypersensitivity to diltiazem. Sick sinus syndrome without pacemaker. Second or third degree AV block without pacemaker. Severe left ventricular dysfunction or decompensated heart failure. Severe hypotension. Concurrent IV verapamil or IV beta-blockers. WPW syndrome with AF (risk of VF acceleration). Cardiogenic shock.

Drug Interactions

Beta-blockers: additive negative chronotropy and dromotropy — risk of symptomatic bradycardia or AV block. Monitor ECG. Digoxin: diltiazem increases digoxin plasma levels (reduced renal clearance) — increased toxicity risk; monitor digoxin levels. Cyclosporin: diltiazem markedly increases cyclosporin levels — significant dose reduction required. CYP3A4 substrates: diltiazem is a CYP3A4 inhibitor — increases levels of statins (atorvastatin, simvastatin), tacrolimus, midazolam, and others. Amiodarone: additive conduction depression — potentially severe bradycardia or AV block.

Cardiovascular drugs have numerous clinically significant, potentially dangerous drug interactions. A comprehensive medication review by a cardiologist or clinical pharmacist is essential before initiating or changing any cardiac medication. Patients must inform all healthcare providers (including dentists, surgeons, and emergency physicians) of all their cardiovascular medications.

Adverse Effects

Common: Bradycardia, AV block (diltiazem suppresses SA/AV nodal calcium channels), constipation, headache, flushing, and oedema. Uncommon: Heart failure exacerbation in patients with impaired LV function. Rare: Severe bradyarrhythmia or complete heart block — ECG monitoring warranted at initiation.

Special Population Considerations

Heart rate monitoring: Baseline and follow-up ECG and resting heart rate monitoring are important at treatment initiation and dose titration — diltiazem’s negative chronotropic effect requires monitoring to avoid symptomatic bradycardia. Target resting heart rate in angina management: 55–60 bpm. Concomitant beta-blockers: Use with extreme caution — significant risk of additive AV block and bradycardia; use only under specialist supervision with ECG monitoring. Hepatic impairment: Diltiazem is hepatically metabolised — reduce dose in hepatic impairment.

Storage and Handling

Store Channel SR 90mg at room temperature (15–25°C) in a dry location away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children. Do not use beyond the printed expiry date. Nitroglycerin preparations require special storage in airtight glass containers away from heat — plastic and light degrade GTN. Enoxaparin: store at room temperature; do not freeze.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children. Do not use after the expiry date.

Q: What should I do if I miss a dose?
A: Take the missed dose as soon as you remember unless it is nearly time for the next scheduled dose. Never double-dose. Do not stop beta-blockers, anticoagulants, or anti-anginal medications abruptly without medical advice.

Q: What is the difference between diltiazem IR, SR, and CD?
A: Immediate-release (IR) diltiazem requires 3–4 times daily dosing due to a short half-life. Sustained-release (SR) formulations provide twice-daily dosing with smoother plasma levels. Controlled-delivery (CD) or extended-release (XL) capsules provide once-daily dosing with the most consistent 24-hour drug levels. SR and CD formulations must be swallowed whole — crushing or chewing destroys the controlled-release mechanism and causes dose dumping.

Evidence Base and Cardiovascular Guidelines

The active ingredient in Channel SR 90mg has been evaluated in landmark randomised controlled trials and is supported by major international cardiovascular guidelines including those from the European Society of Cardiology (ESC), American College of Cardiology/American Heart Association (ACC/AHA), American Heart Association, National Institute for Health and Care Excellence (NICE), and relevant national cardiovascular specialist bodies. These guidelines represent evidence-based consensus on optimal pharmacological management of cardiovascular conditions and are regularly updated as new clinical evidence emerges.

Cardiovascular disease management has undergone transformative advances over the past three decades — from the landmark MERIT-HF, CAPRICORN, and EMPHASIS-HF trials establishing guideline-directed medical therapy for heart failure, to the COURAGE trial for stable angina, EINSTEIN for anticoagulation, and ADVANCE-HF for newer agents. Patients benefit most when their individual pharmacotherapy aligns with current evidence-based guidelines.

Patient Counselling Points

• Never stop abruptly: Beta-blockers, anti-anginal drugs, and anticoagulants must never be stopped suddenly without medical guidance — abrupt withdrawal can trigger angina rebound, myocardial infarction, arrhythmia, or thromboembolic events.
• Carry a medication list: All patients on cardiovascular drugs should carry a current medication list for any medical encounter — including surgical, dental, and emergency care. Drug interactions in cardiovascular patients can be life-threatening.
• Regular monitoring: Blood pressure, ECG, renal function, electrolytes (for diuretics), INR (for warfarin), platelet count (for heparins), and cardiac biomarkers as appropriate should be monitored at intervals determined by your cardiologist.
• Lifestyle integration: Pharmacotherapy delivers best results alongside appropriate lifestyle modification: Mediterranean diet, regular aerobic exercise, smoking cessation, moderate alcohol, sodium restriction for hypertension and heart failure.

Cardiovascular Disease Context and Clinical Management Principles

Cardiovascular disease (CVD) remains the leading cause of death globally, responsible for approximately 18 million deaths annually — representing 32% of all global mortality. Coronary artery disease, heart failure, hypertension, stroke, and peripheral arterial disease collectively impose an enormous burden of mortality, morbidity, and reduced quality of life worldwide. The last five decades have witnessed transformative advances in cardiovascular pharmacotherapy — from the introduction of beta-blockers and ACE inhibitors, through the development of statins and thrombolytics, to the current era of guideline-directed medical therapy with proven mortality-reducing agents for heart failure, and novel anticoagulants revolutionising stroke prevention in atrial fibrillation.

Effective cardiovascular disease management requires integration of pharmacological therapy with lifestyle modification (Mediterranean diet, regular aerobic exercise, smoking cessation, alcohol moderation, sodium restriction), risk factor control (blood pressure, lipid management, glycaemic control, weight management), and appropriate interventional or surgical procedures where indicated. Pharmacotherapy alone, without lifestyle integration and risk factor management, provides suboptimal benefit — drugs and lifestyle modification are synergistic, not alternative, approaches.

Hypertension: The Silent Cardiovascular Risk Factor

Hypertension affects approximately 1.28 billion adults worldwide, yet only 21% of hypertensive adults have their blood pressure adequately controlled. Uncontrolled hypertension is the leading modifiable risk factor for stroke, coronary artery disease, heart failure, renal failure, and peripheral arterial disease. The relationship between blood pressure and cardiovascular risk is continuous — even high-normal blood pressure (130–139/85–89 mmHg) carries increased cardiovascular risk compared to optimal levels.

Current international guidelines (ESC/ESH, ACC/AHA, NICE) recommend initial drug therapy for hypertension with one of three evidence-based drug classes: angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs); calcium channel blockers (CCBs); or thiazide/thiazide-like diuretics. Most patients with stage 2 hypertension (≥160/100 mmHg) require combination therapy from initial diagnosis. Fixed-dose combination tablets — such as those in this product range — improve adherence and simplify therapy for patients requiring multiple agents.

Angina Pectoris: Management Principles

Stable angina pectoris affects over 110 million people globally and represents myocardial ischaemia occurring predictably with exertion or emotional stress, relieved by rest or sublingual nitroglycerin within minutes. The management goal is threefold: symptom relief, prevention of disease progression and MI, and improvement of quality of life. First-line symptomatic therapy uses beta-blockers and/or calcium channel blockers as rate-limiting or vasodilatory agents; long-acting nitrates or nicorandil are added when first-line therapy is insufficient. For resistant symptoms, trimetazidine or ivabradine (when HR remains elevated) provide additional anti-anginal mechanisms. When pharmacological therapy fails to control symptoms adequately, coronary revascularisation (PCI or CABG) should be considered.

Quality Standards and Evidence Base

The active ingredients in products in this range have been evaluated in landmark randomised controlled trials that form the foundation of evidence-based cardiovascular medicine: MERIT-HF (metoprolol succinate in HFrEF), CAPRICORN and COPERNICUS (carvedilol in post-MI LV dysfunction and HFrEF), BEAUTIFUL (ivabradine in stable CAD), SIGNIFY (ivabradine in stable angina), EINSTEIN (enoxaparin in VTE), EXTRACT-TIMI 25 (enoxaparin in STEMI), and IONA (nicorandil in stable angina). Major cardiovascular guidelines from the ESC, ACC/AHA, and NICE incorporate these drugs into evidence-based treatment algorithms based on the totality of this evidence.

Products are manufactured in compliance with Good Manufacturing Practice (GMP) standards required by national and international pharmaceutical regulatory authorities, ensuring consistent quality, identity, strength, and purity. Patients should always obtain prescription cardiovascular medications from licensed pharmacies with valid prescriptions to ensure receipt of authentic, properly stored, quality-assured products.

Important Medical Disclaimer

This product information guide is provided for general educational purposes only, prepared in accordance with YMYL (Your Money Your Life) content standards. All information draws on regulatory prescribing information, peer-reviewed cardiology literature, and established clinical guidelines. It does not replace professional medical advice, diagnosis, or treatment from a qualified cardiologist, physician, or pharmacist. Cardiovascular drug therapy decisions must be individualised by a licensed healthcare provider with full knowledge of the patient’s cardiac status, comorbidities, and concurrent medications. Self-diagnosis and self-treatment of cardiovascular conditions can be dangerous and life-threatening. Always consult a qualified cardiologist or physician before starting, changing, or stopping any cardiovascular medication.